Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25133837 | 0.98 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL27003917 | 0.98 | GPR119 (0.54) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL29132139 | 0.98 | GPR119 (0.57) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL29132229 | 0.96 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL25133987 | 0.96 | GPR119 (0.52) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL19297519 | 0.93 | GPR119 (0.49) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL13128899 | 0.93 | GPR119 (0.49) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL15000457 | 0.93 | GPR119 (0.49) | GPR119HPGDRECQLEPHX1KDM4E | |
| Hydrochloric Acid SCHEMBL30619254 | 0.91 | GPR119 (0.48) | GPR119HPGDRECQLEPHX1KDM4E | |
| SCHEMBL2770208 | 0.89 | GPR119 (0.61) | GPR119HPGDRECQLEPHX1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20260042788-A1 | STAT6 COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12545659-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-12528785-B2 | MDM2 degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| WO-2025262297-A1 | PROTAC DEGRADERS OF MLLT1 AND/OR MLLT3 | DARK BLUE THERAPEUTICS LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-9051283-B2 | Guanidine compound | ASTELLAS PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20130143860-A1 | GUANIDINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2013-06-06 | — | — | US | disclosed |
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-09-30 | — | — | US | disclosed |
| WO-2009045313-A2 | OXYPIPERIDINE DERIVATIVES AS HISTAMINE RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| EP-1646620-B1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | ELAN PHARMACEUTICALS, INC. | 2007-02-08 | — | — | US | disclosed |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | BAILEY JAMES M | 2006-11-02 | — | — | US | disclosed |
| EP-1646620-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005014571-A1 | SUBSTITUTED PIPERIDINES AS HISTAMINE H3 RECEPTOR LIGANDS | GLAXO GROUP LIMITED (GB) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545659-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK4 | GPR119 1443/4885HPGD 4028/4885RECQL 3224/4885 |
| US-20260042788-A1 | STAT6 COMPOUNDS | STAT6, IL6ST, NFATC1 | GPR119 496/4885HPGD 3461/4885RECQL 3901/4885 |
| US-20100249098-A1 | OXYPIPERIDINE DERIVATIVES AND METHODS OF USE THEREOF | OPRK1, GPR119, OPRD1 | GPR119 2/4885HPGD 645/4885RECQL 4249/4885 |
| US-12528785-B2 | MDM2 degraders and uses thereof | MDM2, ADRM1, RBX1 | GPR119 3298/4885HPGD 4011/4885RECQL 553/4885 |
| US-20130143860-A1 | GUANIDINE COMPOUND | GUCY1A1, VAPA, VAPB | GPR119 156/4885HPGD 2872/4885RECQL 4617/4885 |
| US-20060247227-A1 | Substituted piperidines as histamine h3 receptor ligands | HRH3, HRH4, HRH1 | GPR119 216/4885HPGD 1364/4885RECQL 3948/4885 |
| US-20260098049-A1 | KRAS MODULATING COMPOUNDS | KRAS, NRAS, HRAS | GPR119 2528/4885HPGD 3940/4885RECQL 1615/4885 |
| US-20070032475-A1 | Novel compounds useful for bradykinin B1 receptor antagonism | BDKRB1, BDKRB2, NPBWR1 | GPR119 165/4885HPGD 262/4885RECQL 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.